The recurrence group had significantly larger tumors than the no-recurrence group.
A PSA nadir below 0.4 ng/mL offers the best long-term biochemical progression-free survival, study shows.
Men who underwent whole-gland cryoablation had an estimated 5-year biochemical progression-free survival rate of 59.1%.
Study reveals comparable rates of freedom from biochemical failure at 5 years.
Lapascopic and percutaneous cryoablation for small renal masses are associated with similar survival, researchers say.
Focal and whole-gland approaches may provide alternatives for recurrent PCa after radiotherapy
Patients who underwent the procedure experienced no significant change in renal function.
Renal and Urology News Articles
- For Treating Uremic Pruritus, Evidence is Strongest for Gabapentin
- IgG-Degrading Enzyme Desensitizes, Permits HLA-Incompatible Transplant
- Evaluating Practice Options in the Shifting Health Care Landscape
- Melanoma Risk Higher in Kidney Transplant Recipients
- Kidneys From Octogenarian Donors Show Similar Survival
Sign Up for Free e-newsletters
NEPHROLOGY & UROLOGY NEWS
- Acute Kidney Injury (AKI)
- Chronic Kidney Disease (CKD)
- Contrast Nephropathy
- Cardiovascular Disease (CVD)
- Diabetic Nephropathy
- End-stage Renal Disease (ESRD)
- Lupus Nephritis
- Peritoneal Dialysis
- Secondary Hyperparathyroidism (SHPT)